Compare Abbott Laboratories (ABT) vs Berkshire Hathaway Inc Class B (BRK.B) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Berkshire Hathaway Inc Class B — how do they compare? Abbott Laboratories trades at $95.7 (market cap $166.94B), while Berkshire Hathaway Inc Class B trades at $501.38. The key difference: Abbott Laboratories pays a 2.63% dividend while Berkshire Hathaway Inc Class B pays none, and Berkshire Hathaway Inc Class B is trading nearer its 52-week high, Abbott Laboratories nearer its low. Which is the better fit depends on your goals.
| ABT | BRK.B | |
|---|---|---|
Market Cap | $166.94B | — |
Sector | Health | Financials |
52-Week High | $136.62 | $513.70 |
52-Week Low | $82.57 | $459.10 |
Enterprise Value | $193.69B | — |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
BRK.B trades at $502.09, down 0.91% today, with a bullish technical signal driven by moving averages. Support levels are near $494–$501, while resistance sits at $509–$517. Analyst consensus is positive, with 57% buy ratings, though key financial ratios like P/E and P/B are not provided in the data. The stock shows strong momentum with ADX indicating a robust trend.
The outlook for BRK.B is cautiously optimistic given bullish technicals and analyst support, but the absence of recent fundamental data limits valuation clarity. Risks include market volatility and reliance on broader economic conditions. Investors should await updated earnings reports for a fuller picture of intrinsic value and growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Berkshire Hathaway Inc Class B
Berkshire Hathaway is a holding company with diverse subsidiaries, primarily in insurance through Geico and its reinsurance groups. It reinvests profits into various industries, owning Burlington Northern Santa Fe (railroad), Berkshire Hathaway Energy, and major manufacturing, service, and retail businesses like Precision Castparts and Lubrizol. The company operates in a highly decentralized manner.
Read more on BRK.B →
